Trial Profile

A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Romidepsin (Primary)
Indications Anaplastic large cell lymphoma; Cutaneous T-cell lymphoma; Large granular lymphocytic leukaemia; Mycosis fungoides; Sezary syndrome; T-cell leukaemia; T-cell lymphoma
Focus Adverse reactions

Most Recent Events

30 Jan 2026 Status changed from active, no longer recruiting to completed.
01 Aug 2025 Planned End Date changed from 1 Jul 2025 to 15 May 2026.
12 Jun 2025 The protocol has been amended to addition in safety primary endpoints.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com